C3 International will convene its Davos of Healthcare summit in Silicon Valley on 27 April 2026, and has built the 2026 edition around a partnership with King Faisal Specialist Hospital of Riyadh, PR Newswire reported. The event, to be held at the venture firm Plug and Play in Sunnyvale, California, is a promotional gathering, and its headline figures come from the organisers rather than an independent count. PR Newswire said a keynote would be given by Leon Panetta, the former United States defence secretary, on healthcare and biotechnology as matters of national security. Ransel Potter, the founder and managing partner of C3 International, said the group had always been about “moving beyond conversation to execution”.
Health as national security
Panetta’s presence set the framing. PR Newswire said his keynote would treat healthcare and biotechnology as foundations of geopolitical stability, an argument that health capacity is now part of national strategy rather than a purely clinical matter. That pitch suits the room. It gathers hospital systems, venture and private-equity money and AI companies in one place, and it lets a state-backed hospital like King Faisal present itself to that audience as an instrument of policy as much as a provider of care.
The Saudi anchor
King Faisal Specialist Hospital is the summit’s global strategic partner, and its role is the part of the announcement with the clearest link to cross-border care. Dr Björn Zoëga, the chief executive of the Riyadh hospital, is due to present the institution’s approach to adopting new clinical technology, PR Newswire reported. King Faisal is the hospital that performed what it called the world’s first fully robotic heart transplant, a procedure covered when Saudi Arabia used it to headline a medical-travel push. That reputation is what Riyadh is spending on. Vision 2030 has made foreign-patient care an explicit target. A hospital that can claim a world first is the kind of asset the kingdom’s Vision 2030 healthcare push is built to show off.
Who is coming, and the pitch
Over 300 senior leaders are expected, PR Newswire said, with named participants including Mayo Clinic Platform, Cleveland Clinic, MD Anderson Cancer Center, the UT Austin Dell Medical School, the data firm Innovaccer, Scale AI and HSBC. The summit’s stated focus spans AI diagnostics, genomics and next-generation therapeutics, cross-border regulation and hospital data systems, the release said. A pitch competition, run with King Faisal Specialist Hospital and Plug and Play, drew more than 125 applications from over 25 countries, among them the United States, the United Kingdom, Switzerland, India and Singapore. Of those companies, the release said, 57 per cent had already raised angel or venture funding and more than 85 per cent were seeking further capital. Oncology, neuroscience, surgical innovation, and paediatric and women’s health were the strongest clinical categories, according to the organisers.
Announcement, not deployment
None of this is medical tourism yet, and the distinction is the point. A summit generates letters of intent, pitch decks and funding rounds, and those are inputs rather than treated patients. Announcements of this kind are common in medical travel, where a memorandum of understanding or a headline delegation count often stands in for patients who have not yet arrived. What decides whether any of it reaches an international patient is deployment inside a hospital, and on that the release could offer only Dr Zoëga’s planned talk and the promise of a validation pathway. The clinical technologies on show, from AI diagnostics to genomics, tend to move from a conference stage to a working ward slowly. The questions of safety and regulation travel with them, as debate over the risks of AI in healthcare has set out.
What to watch
PR Newswire is a paid distribution wire, and the summit had not taken place when the release went out, so its numbers should be read as claims rather than results. The organisers named no ticket price, no confirmed patient-facing outcome and no figure for deals closed at earlier editions, which is the usual shape of a pre-event release. The checkable questions come after 27 April. Whether King Faisal Specialist Hospital signs or deploys anything from the pitch cohort, whether the 300-strong turnout materialises, and whether any winning company runs a clinical pilot in Riyadh will be visible in the months after the summit. A hospital that markets itself on a robotic heart transplant will be judged on the next procedure, not the next conference.
